[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Unity Health Toronto\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":690},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,59,0,25,[9,54,83,115,140,175,206,239,268,292,322,356,369,394,416,441,463,491,517,539,564,593,617,639,665],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100054285","cyanoacrylate-glue-versus-absorbable-gelatin-sponge-for-gastric-varices-100054285",false,"NCT07699354","Cyanoacrylate Glue Versus Absorbable Gelatin Sponge for Gastric Varices","Cyanoacrylate Glue Versus Absorbable Gelatin Sponge for Endoscopic Treatment of Gastric Varices (CoAGS-GV): A Randomized, Patient- and Assessor-Blinded, Non-Inferiority Trial","CoAGS-GV","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Gastric varices deemed suitable for EUS-guided endoscopic treatment.\n* History of suspected gastric variceal bleeding or active gastric variceal bleeding, with treatment intended for secondary prophylaxis.\n* Ability to provide informed consent directly or through a substitute decision maker.\n* Willingness and ability to undergo clinical follow-up, EUS assessment, and CT imaging.\n\nExclusion Criteria:\n\n* Inability or unwillingness to provide informed consent directly or through a substitute decision maker.\n* No gastric varix present, or gastric varix too small or not amenable to combination therapy.\n* Contraindication to therapeutic EUS or endoscopy.\n* Contraindication to any study material used in the assigned treatment arm.\n* Contraindication to contrast-enhanced CT, if not clinically manageable.\n* Inability to complete planned follow-up.\n* Pregnancy.\n* Any clinical situation in which the treating endoscopist determines that randomization would be unsafe or inappropriate.","ALL","18 Years",{"count":21,"type":22},64,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study compares two endoscopic ultrasound-guided treatments for gastric varices, which are enlarged veins in the stomach that can bleed. Both treatments use small coils placed into the varix. One group will receive coils with cyanoacrylate medical glue, and the other group will receive coils with absorbable gelatin sponge.\n\nThe purpose of the study is to determine whether absorbable gelatin sponge with coils is not worse than cyanoacrylate glue with coils for closing off gastric varices, and to compare safety outcomes. Participants will be randomly assigned to one of the two treatment groups. Participants and outcome assessors will not know which treatment was used, but the doctor performing the procedure will know.\n\nAfter the procedure, participants will be followed for up to 12 months. Follow-up may include clinical assessments, questionnaires about health and quality of life, CT imaging shortly after the procedure, and repeat endoscopic ultrasound assessments to evaluate whether the gastric varix has been successfully treated.",[28,29,30],"Gastric Varices Bleeding","Gastric Varices","Portal Hypertension",[32,33,34,35,36,37,38,39,40],"Endoscopic ultrasound","EUS-guided therapy","Portal hypertension","Cyanoacrylate glue","Absorbable gelatin sponge","Gelfoam","Coil embolization","Variceal obliteration","Secondary prophylaxis","NOT_YET_RECRUITING","2026-07-09",{"date":44,"type":45},"2026-07-13","ACTUAL",{"date":47,"type":22},"2026-08-01",{"date":49,"type":22},"2029-08-01",{"name":51,"class":52},"Unity Health Toronto","OTHER",1,{"id":55,"slug":56,"hasResults":12,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":67,"conditions":68,"keywords":73,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":53},"100053870","phase-1-contralateral-corticosteroid-injection-in-total-knee-arthroplasty-100053870","NCT06809998","COntralateral CorticoSTeroid Injection in Total Knee Arthroplasty","COSTI: COntralateral CorticoSTeroid Injection in Total Knee Arthroplasty - A Triple Blinded, Randomized Controlled Trial Pilot Study","COSTI","Inclusion Criteria:\n\n* Patients 18 years of age and older\n* Primary osteoarthritis diagnosis with indication for primary elective unilateral TKA\n* No previous contralateral knee injections (steroids\u002Fbiologics) within one year of study\n* Not scheduled for bilateral TKA or a subsequent staged contralateral TKA within the next six months\n* No previous or active infection or trauma (osseous\u002Fligamentous\u002Fextensor mechanism) on the contralateral knee\n* Contralateral knee pain \\& symptoms - defined as a VAS of \\>4\u002F10 at initial pre-op visit\n* Contralateral knee OA quantified as: Kellgren and Lawrence grade \\>2-4\n\n  * Assessed by PI (AK) who will not be contributing any patients to the study through examination of blinded knee radiographs (3 views: AP\u002Flateral\u002FSunrise)\n* Patient is able to read and understand English and provide informed consent to participation in the study\n\nExclusion Criteria:\n\n* Other aetiologies of OA that warrants TKA (inflammatory or post traumatic arthritis)\n* Cognitive impairment (dementia, Alzheimer's, uncontrolled delirium) which will prevent patients from completing primary outcome measure or comply with follow-up requirements\n* Previous TKA or ORIF or nailing on either knee\n* Previous or active knee infection or extensor mechanism disruption\n* Previous arthroscopy on either knee\n* Medical contraindication to elective TKA surgery",{"count":63,"type":22},60,[65,66],"PHASE1","PHASE2","Through a triple-blinded randomized control trial, the primary purpose of this pilot study is to assess the efficacy of administering peri-operative contralateral corticosteroid injection in patients undergoing TKA. The secondary outcome was to assess the effect of contralateral corticosteroid injection on pain and functional outcomes of patients undergoing TKA.",[69,70,71,72],"Total Knee Anthroplasty","Osteoarthritis(Primary)","Osteoarthritis (OA) of the Knee","Bilateral Knee Osteoarthritis",[60,74,75],"Total Knee Arthroplasty","Corticosteroid Injection","RECRUITING",{"date":44,"type":45},{"date":79,"type":45},"2025-01-24",{"date":81,"type":22},"2027-08-30",{"name":51,"class":52},{"id":84,"slug":85,"hasResults":12,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":94,"conditions":95,"keywords":100,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},"100594271","phase-4-glucagon-like-peptide-1-receptor-agonists-in-patients-receiving-maintenance-dialysis-100594271","NCT07017270","Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis","GUARD-1","Inclusion Criteria:\n\n1. Age ≥ 18\n2. Receiving chronic maintenance hemodialysis or peritoneal dialysis for ≥ 90 days\n3. confirmed DM2 based on medical history and current or prior receipt of an oral hypoglycemic agent and\u002For insulin.\n4. Ability to provided informed consent or through their substitute decision maker\n\nExclusion Criteria:\n\n1. Type 1 DM\n2. Use of a GLP-1-RA within 30 days prior to screening\n3. Personal or first-degree relative(s) with a history of type 2 multiple endocrine neoplasia syndrome or medullary thyroid cancer, or acute pancreatitis (within 180 days of study screening)\n4. Confirmed pregnancy, women of childbearing potential\n5. Known hypersensitivity to GLP-1-RA\n6. Expected to recover kidney function, stop hemodialysis, pursue palliative care, or transplantation within 6 months\n7. Enrolment in another clinical trial judged by the investigator to interact with the effect of GLP1-RA",{"count":91,"type":22},100,[93],"PHASE4","This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.",[96,97,98,99],"Kidney Disease, Chronic","Diabetes","Dialysis","End Stage Kidney Disease (ESRD)",[98,101,102,103,104,105],"Type 2 diabetes","semaglutide","end stage kidney disease","GLP1","GLP1RA","2026-06-22",{"date":108,"type":45},"2026-06-26",{"date":110,"type":45},"2025-11-27",{"date":112,"type":22},"2027-09",{"name":51,"class":52},2,{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":23,"phases":125,"briefSummary":126,"conditions":127,"keywords":131,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":134,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":53},"100545753","phase-2-psilocybin-assisted-cognitive-processing-therapy-for-chronic-ptsd-100545753","NCT06386003","Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD","Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label Trial","Inclusion Criteria:\n\n1. Meet Diagnostic and Statistical Manual-5th edition (DSM-5) criteria for current PTSD with a duration of 6 months or longer assessed by study psychiatrist;\n2. Have a Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score of 50 or higher, indicating moderate to severe PTSD symptoms;\n3. Are willing to refrain from taking any psychiatric medications during the study period.\n\nExclusion Criteria:\n\n1. Are pregnant or nursing, or are women of child bearing potential who are not practicing an effective means of birth control;\n2. Have a history of or a current primary diagnosis of psychotic disorder, schizophrenia, delusional disorder, borderline personality disorder, schizoaffective disorder, bipolar disorder or, dissociative identity disorder;\n3. Have evidence or history of coronary artery disease or cerebral or peripheral vascular disease, hepatic disease with abnormal liver enzymes, or any other medical disorder judged by the investigator to significantly increase the risk of psilocybin administration;\n4. Have hypertension using the standard criteria of the American Heart Association (values of 140\u002F90 or higher assessed on three separate occasions;\n5. History of seizure disorder;\n6. Uncontrolled insulin-dependent diabetes;\n7. Recent stroke, intracranial or subarachnoid hemorrhage (\\\u003C 1 year from signing of informed consent form \\[ICF\\]), recent myocardial infarction (\\\u003C 1 year from signing of ICF), clinically significant arrhythmia (\\\u003C 1 year from signing of ICF);\n8. Have liver disease with the exception of asymptomatic subjects with Hepatitis C who have previously undergone evaluation and successful treatment;\n9. Lifetime history of substance-induced psychosis;\n10. Lifetime history of substance use disorder with a hallucinogen;\n11. History of alcohol use disorder in the past 3 months.","65 Years",{"count":124,"type":22},15,[66],"This is an open-label trial evaluating feasibility, tolerability, safety and efficacy of psilocybin assisted cognitive processing therapy for chronic Posttraumatic Stress Disorder (PTSD).",[128,129,130],"Post Traumatic Stress Disorder","PTSD","Chronic PTSD",[128,132,133],"Psilocybin","Cognitive Processing Therapy",{"date":108,"type":45},{"date":136,"type":22},"2026-06",{"date":138,"type":22},"2027-01",{"name":51,"class":52},{"id":141,"slug":142,"hasResults":12,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":23,"phases":148,"briefSummary":149,"conditions":150,"keywords":158,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":114},"100622718","mainstreaming-genetics-evaluation-of-a-digital-application-to-scale-and-spread-oncologist-initiated-genetic-testing-100622718","NCT07387263","Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing","Inclusion Criteria:\n\n* Receiving germline testing related to primary cancer condition initiated by oncologist\n* 18 years old or older.\n* Speak and read English\n\nExclusion Criteria:\n\n* Receiving cancer genetic testing via a referral to a genetics clinic\n* Do not speak or read English\n* Under 18 years of age\n* Determined to have diminished, marginal and or fluctuating decisional capacity\n* Lack access to internet or an electronic device",{"count":147,"type":22},180,[25],"Genetic testing can alter therapy and surgical management for cancer patients and is therefore indicated as a first-line test for many newly diagnosed patients, including breast, ovarian, pancreatic, prostate and colon\u002FGI patients. To reduce pressure on already constrained genetics clinics across Canada, some cancer centres are 'mainstreaming' genetic testing - whereby genetic testing is initiated and mediated by oncologists without traditional pre-test genetic counseling (GC) often using some form of paper-based patient pamphlets or videos. There is no standard, evidence-based approach to mainstreaming, leading to significant practice variation, a lack of coordinated care and ultimately, negative psychological impacts on patients. Digital solutions can address these gaps by providing a standardized, coordinated and patient-centered approach to deliver cancer genetic education. However, digital solutions for providing cancer genetics services are uncommon and clinical-effectiveness and service delivery outcomes have not been well-assessed. This study will test a digital mainstreaming platform called the Genetics Adviser for Mainstream care to assess its effectiveness in improving psychological outcomes and patient-centred care for mainstream cancer patients compared to standard of care.",[151,152,153,154,155,156,157],"Cancer","Breast Cancer","Prostate Cancer","Colon Cancer","GI Cancers","Ovarian Cancer","Pancreatic Cancer",[159,160,161,162,163,151,164,165,166],"Cancer Genetic Testing","Randomized Controlled Trial","Digital Tool","Mainstreaming","Genetic counseling","Genetic testing","Service Delivery","Alternative service delivery model","2026-06-19",{"date":169,"type":45},"2026-06-24",{"date":171,"type":45},"2026-04-30",{"date":173,"type":22},"2027-03",{"name":51,"class":52},{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":181,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":23,"phases":184,"briefSummary":185,"conditions":186,"keywords":193,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":199,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":205},"100551076","the-genetics-navigator-evaluating-a-digital-platform-for-genomics-health-services-100551076","NCT06455384","The Genetics Navigator: Evaluating a Digital Platform for Genomics Health Services","Inclusion:\n\n* Adult patients (18 years of age or older) who are referred to participating clinicians at Mount Sinai Hospital for clinical genetic testing.\n* Parents\u002Flegal guardians (18 years of age or older) of pediatric patients who are referred to participating clinicians at SickKids for clinical genetic testing.\n\nExclusion:\n\n* Known not to be eligible for clinical genetic testing in Ontario\n* Requires urgent clinical genetic testing or prenatal genetic testing\n* Not fluent in English (speaking and reading)",true,{"count":183,"type":22},170,[25],"Genetic testing (GT) (including targeted panels, exome and genome sequencing) is increasingly being used for patient care as it improves diagnosis and health outcomes. In spite of these benefits, genetic testing is a complex and costly health service. This results in unequal access, increased wait times and inconsistencies in care. The use of e-health tools to support genetic testing delivery can result in a better patient experience and reduced distress associated with waiting for results and empower patients to receive and act on medical results. We have previously developed and tested an interactive, adaptable and patient-centred digital decision support tool (Genetics ADvISER) to be used for genetic testing decision making, and have now developed the Genetics Navigator (GN), a patient-centred e-health navigation platform for end-to-end genetic service delivery. The objective of this study is to evaluate the effectiveness of the GN in an RCT in reducing distress with patients and parents of patients being offered genetic testing. Results of this trial will be used to establish whether the GN is effective to use in practice. If effective, GN could fill a critical clinical care gap and improve health outcomes and service use by reducing counselling burden as well as overuse, underuse and misuse of services. These are concerns policy makers seek to address through the triple aims of health care1. This study represents a significant advance in personalized health by assessing the effectiveness of this novel, comprehensive e-health platform to ultimately improve genetic service delivery, accessibility, patient experiences, and patient outcomes.",[187,188,189,190,191,151,192],"Cardiac Conditions","Connective Tissue Diseases","Retinal Disease","Epilepsy in Children","Neurodevelopmental Disorders","Polyposis",[194,160,195,196,197,198],"Genomic Sequencing","Clinical Utility","Personal Utility","Decision Aid","Incidental Findings",{"date":169,"type":45},{"date":201,"type":45},"2025-10-28",{"date":203,"type":22},"2027-07",{"name":51,"class":52},3,{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":23,"phases":217,"briefSummary":218,"conditions":219,"keywords":222,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":53},"100625180","supporting-social--economic-equity-disrupting-cycles-of-homelessness-and-nurturing-growth--empowerment-100625180","NCT07419282","Supporting Social & Economic Equity, Disrupting Cycles of Homelessness, And Nurturing Growth & Empowerment","Supporting Social & Economic Equity, Disrupting Cycles of Homelessness, And Nurturing Growth & Empowerment (SEED CHANGE): A Mixed Methods Quasi-experimental Trial of Economic, Social, and Identity Capital Supports for Youth Transitioning Out of Homelessness in Ontario, Canada","SEED CHANGE","Inclusion Criteria:\n\n* Aged 18 - 24 years\n* Experienced homelessness (defined as unstable\u002Ftime-limited housing arrangements like shelter stays, foster care, or couch surfing) for at least seven consecutive days in the past year\n* Living in market rent housing (defined as non-subsidized housing, inclusive of both formal and informal rental agreements) in the Greater Toronto Area or Niagara Region for at least one month preceding study start\n* Willing to actively participate in all components of the intervention\n* Able to legally work in Canada (includes having a valid Social Insurance Number)\n* Able to provide free and informed consent\n* Able to understand English well enough to give consent and participate in the intervention and data collection\n\nExclusion Criteria:\n\n* In imminent danger of losing their housing (e.g., facing eviction)\n* Planning to move out of the Greater Toronto Area or Niagara Region in the next 18 months\n* Employed full-time or enrolled in an education or training program that requires a long-term (\\>4 weeks) full-time work placement (coinciding with the duration of the study intervention)\n* Receiving rent subsidies (does not include shelter allowance through social welfare programs such as Ontario Works or the Ontario Disability Support Program)\n* Enrolled in a program or study with features similar to the SEED CHANGE intervention (e.g., 1:1 coaching, supported employment, group program targeting identity\u002Fsocial capital)","24 Years",{"count":216,"type":22},42,[25],"The goal of the SEED CHANGE pilot study is to co-design and test a wraparound intervention for young people transitioning away from homelessness. This study will provide information about the types of supports these young people need to live meaningful and thriving lives, and the best ways to deliver these supports. The main questions it aims to answer are:\n\n* Is the wraparound intervention feasible? (i.e., Will young people engage in the study and supports?)\n* Is the wraparound intervention acceptable? (i.e., Do young people find the supports satisfactory and\u002For beneficial?)\n\nParticipants will engage in an 18-month wraparound intervention including the following supports:\n\n* Job Placement\n* Housing Stabilization Funds\n* Grocery Supplements\n* Community Connections Worker\n* Coaching\n* Tools for Intentional Living Program",[220,221],"Homelessness","Youth",[223,224,225,226,227,228,229,230],"youth","coach","employment","homelessness","transition","socioeconomic inclusion","identity capital","social capital","2026-06-11",{"date":233,"type":45},"2026-06-15",{"date":235,"type":45},"2026-02-25",{"date":237,"type":22},"2029-08",{"name":51,"class":52},{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":18,"minAge":247,"maxAge":4,"enrollmentInfo":248,"targetDuration":250,"studyType":251,"phases":4,"briefSummary":252,"conditions":253,"keywords":255,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":53},"100340541","geriatric-acetabular-fractures-open-reduction-internal-fixation-versus-replacement-100340541","NCT03713853","Geriatric Acetabular fracTures: Open Reduction Internal Fixation Versus Replacement","GATOR: Geriatric Acetabular fracTures: Open Reduction Internal Fixation Versus Replacement - A Large Cohort of Acute Open Reduction Internal Fixation (ORIF) Versus Total Hip Arthroplasty for Geriatric Acetabular Fractures","GATOR","Inclusion Criteria:\n\n* 60 years of age or older\n* Isolated and Displaced (more or equal to 2mm on any radiographic view) fracture of the acetabulum\n* Patient requires surgical treatment, either THA+ORIF or ORIF surgeries\n* Fracture is acute (within 3 weeks of injury)\n* Patient was ambulatory (with or without walking aids) prior to their acetabular fracture injury\n* Patient is able to provide informed consent to participation in the study\n* Patient is able to read and understand English\n\nExclusion Criteria:\n\n* Presence of an active or chronic infection around the fracture (soft tissue or bone)\n* Open\u002Fcompound fracture\n* Bilateral acetabular fractures\n* Pathological fracture excluding osteoporosis\n* Periprosthetic fracture (previous arthroplasty or hardware or ORIF in-situ). Hardware (screws or plates or nails or hemi-arthroplasty) on the femoral side are not excluded.\n* Medical or surgical contraindication to surgery\n* Dementia","60 Years",{"count":249,"type":22},104,"24 Months","OBSERVATIONAL","Management of acetabular (hip) fractures in the geriatric population can be very challenging because of pre-existing medical comorbidities, pre-existing osteoporosis and increased risk of mortality.\n\nThe two most common treatment options for acetabular fractures are either surgical fixation using plates and screws to hold the fractured pieces in the correct position until the fracture has healed or surgical fixation in addition to a total hip replacement.\n\nSurgical fixation requires prolonged immobilization of the affected limb (typically around 6-12 weeks post-operatively), which can lead to disability and other complications. Such patients, especially those who are frail and cognitively impaired, are unable to adhere to the immobilization restrictions, leading to an increased risk of fixation failure.\n\nPatients who underwent open reduction internal fixation (ORIF) of an acetabular fracture were reported to have about 25 times greater incidence of hip replacement compared with general population matched controls.\n\nAdditionally, performing a subsequent hip replacement after a previous surgical fixation (ORIF) of an acetabular fracture, especially in the elderly population, can present a number of technical difficulties including; difficult dissection due to previous incision(s) and scarring, dealing with retained hardware, bony deficiency and the possibility of infected hardware.\n\nThe aim of the study is to perform a large cohort study to assess pain and physical function in patients 60 years and older who have sustained an acetabular fracture.",[254],"Acetabular Fracture",[256,257,258,259],"Total hip replacement","Total hip arthroplasty","Open Reduction internal Fixation","Hip fixation","2026-06-10",{"date":262,"type":45},"2026-06-12",{"date":264,"type":22},"2026-12",{"date":266,"type":22},"2030-12",{"name":51,"class":52},{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":275,"enrollmentInfo":276,"targetDuration":4,"studyType":23,"phases":277,"briefSummary":278,"conditions":279,"keywords":281,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":4},"100643531","functional-electrical-stimulation-for-mdd-100643531","NCT07629050","Functional Electrical Stimulation for MDD","Functional Electrical Stimulation for Major Depressive Disorder: A Pilot Randomized Control Trial","Inclusion Criteria:\n\nPatients will be included if they:\n\n1. Meet the DSM-5 criteria for unipolar MDD with a current MDE without psychotic features, with ≤ 2 failed treatment trials (non-treatment-resistant depression), validated by MINI done by a trained research assistant.\n2. Have no change in the medication regimen or other forms of treatments (e.g., psychotherapy) for at least 4 weeks (28 days) prior to beginning the study, and have no plan to change them during the 20-session treatment period (14 days), and the 4-week post-treatment observation period. This will be established through self-report, in combination with the ATHF filled out by the participant.\n3. Have an MDD diagnosis as confirmed by the MADRS score of ≥7.\n4. Age group between 18 and 70 years of age\n\nExclusion Criteria:\n\nPatients will be excluded if they:\n\n1. History of epilepsy or seizures.\n2. Damage or dysfunction of facial nerves.\n3. Metallic orthopedic implants in the mouth (e.g., plates or screws).\n4. Current fibromyalgia or currently receiving or have received rTMS within the last 28 days before the screening.\n5. History of treatment-resistant depression (TRD) with history of ECT, Magnetic Seizure Therapy, Intravenous Ketamine use in the past or failure of \\>2 antidepressant treatments of adequate duration and dose during the current episode.\n6. Past or current symptoms of mania, hypomania, mixed episodes, psychotic disorders, obsessive-compulsive disorder, post-traumatic stress disorder, active substance abuse or dependence (excluding nicotine and caffeine), neurodegenerative disease, or dementia. This will be confirmed on the MINI (77) administered by a trained research assistant.\n7. Current suicidal intent or plan as demonstrated by a score of ≥4 on MADRS item 10.\n8. Unable to understand instructions in English.\n9. Unable to produce \"Duchenne marker\" expression with FES, secondary to any type of neurological condition or previous botulinum toxin treatments of facial muscles.","70 Years",{"count":63,"type":22},[25],"This study aims to determine whether Functional Electrical Stimulation (FES) of the facial muscles is a safe and effective treatment for major depressive disorder (MDD).",[280],"MDD",[282,283],"Major Depressive Disorder","Functional Electrical Stimulation","2026-06-04",{"date":286,"type":45},"2026-06-08",{"date":288,"type":22},"2026-05-25",{"date":290,"type":22},"2029-03-30",{"name":51,"class":52},{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":18,"minAge":300,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":23,"phases":303,"briefSummary":305,"conditions":306,"keywords":308,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":53},"100494088","phase-3-the-use-of-tranexamic-acid-in-the-treatment-of-symptomatic-subdural-hematoma-100494088","NCT05713630","The Use of Tranexamic Acid in the Treatment of Symptomatic Subdural Hematoma","TRACE STUDY: A Randomized Controlled Trial Using Tranexamic Acid in the Treatment of Subdural Hematoma","TRACE","Inclusion Criteria:\n\n* Patients aged 45 and older weighing between 45-150 kg diagnosed with symptomatic SDH will be included. SDH is defined as unilateral or bilateral crescentic collection of blood (hyper, iso, or hypodense, or mixed density) of greater than or equals to 8 mm in thickness along the cerebral convexity on CT of the head. Symptomatic SDH patients eligible for inclusion are those with SDH with one or more of the following symptoms attributable to the SDH: headache, gait disturbance, confusion or cognitive decline, limb weakness or numbness\u002Fparesthesia, speech or visual disturbance, drowsiness or impaired consciousness, seizures, impaired cognition, or memory loss at the time of assessment.\n\nExclusion Criteria:\n\n\\- Patients will be excluded for any of the following conditions:\n\n1. Asymptomatic for longer than 72 hours\n2. SDH less than 8 mm in maximal thickness\n3. Have an acutely deteriorating neurological status (e.g., brain herniation with pupillary dilation, aneurysm rupture, etc.) that is likely to be fatal within 6 hours or less due to a predominantly acute SDH\n4. Presence of brain contusion larger than 5 cubic centimeters or subarachnoid hemorrhage (SAH) thicker than 10 mm with Glasgow Coma Scale (GCS)\\\u003C 13\n5. Patients with primarily interhemispheric or tentorial SDH\n6. Hypersensitivity to TXA or any of the placebo ingredients\n7. Pregnancy\n8. Irregular menstrual bleeding with unidentified cause\n9. Known acquired colour vision disturbances\n10. Hematuria caused by renal parenchymal disease\n11. Acute and chronic renal insufficiency indicated by estimated Glomerular Filtration Rate (eGFR) ≤ 30 mL\u002Fmin\n12. Concomitant intake of birth control pill and\u002For hormonal replacement therapy, and anti-inhibitor coagulant concentrates (factor VIII inhibitor bypass activity (FEIBA), factor VII, activated factor IX)\n13. Consumption coagulopathy\u002Fdisseminated intravascular coagulation (DIC) in the last 7 days\n14. Not competent to take study medication properly and regularly or not having access to caregiver that is able to comply with study medication administration\n15. Mechanical heart valve\n16. Liver cirrhosis\n17. Recent venous and\u002For arterial thromboembolism within 6 months of study enrolment\n18. SDH caused by intracranial hypotension\n19. Known thrombophilia (e.g., antiphospholipid syndrome)\n20. Any active malignancy: metastatic cancer systemically or to the brain or a primary malignant brain tumour treated within the last 6 months\n21. Previous enrolment in this trial for a prior episode\n22. Time interval \\>3 days from the time of clinical assessment to eligibility assessment\n23. Patients weighing \\\u003C45 kg or \\>150 kg\n24. Patients received any amount of TXA upon admittance to hospital prior to enrolment","45 Years",{"count":302,"type":22},130,[304],"PHASE3","Subdural hematoma (SDH) is a common condition experienced after head injury. Blood collects on the surface of the brain, causing headaches which can progress to confusion, weakness, or even coma. While patients with SDH often receive surgery, not all patients require surgery right away to ease pressure on the brain. After surgery, there can be up to 30 percent chance of more bleeding and the need for more surgeries. Given this, a drug capable of lowering the chance of more bleeding and speeding the recovery of the patient is highly desirable. In this study, we will test a commonly used, cheap drug called Tranexamic Acid (TXA). While the body stops unwanted and sometimes dangerous bleeding naturally by forming blood clots, TXA stops these blood clots from breaking down, which helps to keep bleeding spots plugged. Our previous study showed that TXA helped speed up patients' recovery; but a larger number of patients is necessary to evaluate how well TXA works to reduce bleeding and improve patient-reported outcomes. In this study, regardless of the need for surgery, half of the patients will be randomly assigned to take TXA, while the other half will take a placebo, which is a look-alike substance that contains no active drug. We will measure multiple outcomes over time to determine if TXA is working and lowers healthcare and personal costs, while also taking blood and surgical samples, to better understand how this drug works in SDH patients.",[307],"Subdural Hematoma",[309,310,311,312,313],"symptomatic subdural hematoma","tranexamic acid","TXA","clinical trial","neurosurgery","2026-05-26",{"date":316,"type":45},"2026-05-29",{"date":318,"type":22},"2026-05-20",{"date":320,"type":22},"2030-12-31",{"name":51,"class":52},{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":280,"eligibilityCriteria":328,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":275,"enrollmentInfo":329,"targetDuration":4,"studyType":23,"phases":331,"briefSummary":332,"conditions":333,"keywords":336,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":53},"100580890","phase-2-lemborexant-for-the-treatment-of-residual-insomnia-in-major-depressive-disorder-mdd-100580890","NCT06843187","Lemborexant for the Treatment of Residual Insomnia in Major Depressive Disorder (MDD)","Lemborexant for the Treatment of Residual Insomnia in Adequately Treated Major Depressive Disorder: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged 18 to 70 (inclusive), with a self-reported body mass index (BMI) between 19 and 30 kg\u002Fm2 (inclusive);\n2. Meet criteria for primary MDD diagnosis without psychotic symptoms, as defined by the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5)2, and currently in a MDE, confirmed by the MINI International Neuropsychiatric Interview (MINI)3;\n3. Have not failed more than 2 trials of antidepressant treatments in the current MDE, and have a history of adequate response (clinical outcome rating score of 1 or 2) to at least 1 antidepressant treatment during the current MDE as determined by the Antidepressant Treatment History Form-Short Form (ATHF-SF)4;\n4. Are outpatients;\n5. Did not take non-psychotropic or non-central nervous system (CNS) medications suspected to affect sleep-wake function for at least 4 weeks before starting the study.\n6. Self-reported subjective total sleep time (sTST) ≤ 6.5 hours, subjective sleep onset latency (sSOL) ≥ 30 minutes, and subjective wake after sleep onset (sWASO) ≥ 45 minutes per night. Time spent in bed (either sleeping or attempting to sleep) must be between 7 and 10 hours per night. Self-reported regular bedtime (i.e., the time the participant gets in bed) between 21:00 and 01:00 and regular wake time (i.e., the time the participant wakes and does not go back to sleep) between 05:00 and 10:00;\n7. Confirmation of current insomnia symptoms as determined from responses on the Sleep Diary completed on at least 7 consecutive mornings (minimum 5 of 7 for eligibility), such that sSOL ≥ 30 minutes on at least 3 of the 7 nights and\u002For sWASO ≥ 45 minutes on at least 3 of the 7 nights;\n8. Confirmation of sufficient duration of time spent in bed, as determined from responses on the Sleep Diary on the 7 most recent mornings before the visit, such that there are no more than 2 nights with time spent in bed of duration \\\u003C 7 hours or \\> 10 hours;\n9. Confirmation of regular bedtime (i.e., the time the participant gets in bed) between 21:00 and 01:00 on at least 5 of the 7 preceding nights, and regular wake time (i.e., the time the participant wakes and does not go back to sleep) between 05:00 and 10:00 on at least 5 of the 7 preceding nights.\n10. Have a medically responsible physician (family doctor or psychiatrist) during their enrollment and participation in the trial;\n11. Current 17-Item Hamilton Depression Rating Scale (HAM-D-17)30 score ≥ 8 and reporting an insomnia score of ≥15 on ISI1;\n12. Are able to understand and comply with the requirements of the study, as judged by the investigator(s);\n13. Provide written informed consent before initiation of any study-related procedures;\n14. Own a smartphone and have reliable access to the internet and a browser on which to complete questionnaires.\n\nExclusion criteria:\n\n1. Have taken or participated in any clinical trial of lemborexant and other drugs with the same mechanism (e.g., daridorexant), regardless of treatment outcome;\n2. Have any known sensitivity to lemborexant or their excipients;\n3. A lifetime history (current or previous) of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or psychotic symptoms as determined by the MINI;\n4. Women who are pregnant or lactating (documented by a positive beta-human chorionic gonadotropin \\[beta-hCG\\] or human chorionic gonadotropin \\[hCG\\] urine test with a minimum sensitivity of 25 IU\u002FL or equivalent units of beta-hCG or hCG);\n5. Women who are not using an approved and effective method of contraception or family planning during the study. For example, combined estrogen- and progestogen-containing hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, or implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion and ligation, vasectomized partner, sexual abstinence, or two forms of contraception with any barrier method or oral hormones (ie.g., condom plus diaphragm, condom or diaphragm plus spermicide, oral hormonal contraceptives plus spermicide or condom).\n6. Positive toxicology screening results;\n7. If participating in psychotherapy, must have been in stable treatment for at least 3 months prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions or the therapeutic focus 4 weeks before screening and the entire duration of participation;\n8. Have active suicidal intent as determined by a score of 3 (severe suicidality with a clear plan and\u002For intent) or 4 (very severe: suicidal attempts) on item #3 on the HAM-D-17;\n9. Have had a course of electroconvulsive therapy or intravenous ketamine therapy in the current episode or any previous episode;\n10. Medical history of insomnia associated with another sleep disorder or any condition known to impact sleep. This includes any lifetime diagnosis of sleep-related breathing disorder, periodic limb movement disorder, restless legs syndrome, nightmare disorder, sleep terror disorder, sleepwalking disorder, rapid eye movement (REM) behaviour disorder, narcolepsy, or comorbid nocturia that is causing or exacerbating insomnia;\n11. STOP-Bang5 scores ≥ 5; International Restless Legs Scale (IRLS)6 scores ≥ 16,Epworth Sleepiness Scale (ESS)⁷ ≥ 11\n12. Habitual naps 4 or more days a week, occurring in the late afternoon or evening;\n13. Transmeridian travel across more than 3 time zones in the 2 weeks before screening, or between screening and study baseline, or plans to travel across more than 3 time zones during the study;\n14. Used any modality of treatment for insomnia, including cognitive-behavioural therapy within 2 weeks before screening;\n15. Excessive caffeine use, defined as consuming more than 400 mg of caffeine per day (approximately 4 cups of brewed coffee), or habitual consumption of caffeine after 6:00 p.m., which in the investigator's opinion may contribute to insomnia;\n16. Reports habitually consuming more than 14 drinks containing alcohol per week (females) or more than 21 drinks containing alcohol per week (males);\n17. Used prohibited prescriptions or over-the-counter concomitant medications, or used any medication or sleep aid with known effects on sleep within 2 weeks before screening;\n18. Report a history of sleep-related violent behaviour, or sleep driving, or any other complex sleep-related behaviour (e.g., making phone calls, preparing and eating food);\n19. Diagnosis of substance dependence or abuse within the last 3 months as determined by MINI3;\n20. Have a concomitant major unstable medical illness, cardiac pacemaker, or implanted medication pump;\n21. Have any significant neurological disorder or insult including, but not limited to: any condition likely to be associated with increased intracranial pressure, space occupying brain lesion, any history of seizure except a febrile seizure of infancy, cerebral aneurysm, Parkinson's disease, Huntington's chorea, multiple sclerosis, significant head trauma with loss of consciousness for greater than 5 minutes;\n22. A history of risk factors for Torsade de Pointes (e.g., heart failure, hypokalemia, family history of long QT syndrome) or the use of concomitant medications that prolonged the QTcF interval;\n23. Scheduled for major surgery during the study;\n24. Have a clinical finding that is unstable or that, in the opinion of the investigator(s), would be negatively affected by the study medication or that would affect the study medication (e.g., diabetes mellitus, hypertension, unstable angina);\n25. Have uncorrected hypothyroidism or hyperthyroidism. Subjects needing a thyroid hormone supplement to treat hypothyroidism must have been on a stable dose of the medication for 30 days prior to enrolment;\n26. Have any other condition that, in the opinion of the investigator(s), would adversely affect the subject's ability to complete the study or its measures.\n27. Non-English-speaking individuals because the ability to communicate study information, answer questions accurately and completely about the study, and obtain consent are necessary.",{"count":330,"type":22},30,[66],"The goal of this clinical trial is to learn if Lemborexant works to treat residual insomnia in adults with depression that is being treated. It will also learn about how practical, tolerable, and effective Lemborexant is. The main questions it aims to answer are:\n\n* Does Lemborexant help participants improve sleep and reduce insomnia symptoms?\n* How practical is it to use Lemborexant (how many participants join, drop out, and follow the study rules)? How do participants feel about using it (based on surveys and interviews)?\n\nResearchers will compare Lemborexant to a placebo (a look-alike substance that contains no drug) to see if Lemborexant works to treat residual insomnia in adequately treated major depressive disorder.\n\nParticipants will:\n\n* Take Lemborexant or a placebo every day for 6 weeks (2 weeks at 5 mg then 4 weeks at 10 mg)\n* Complete clinical assessments and in-person study visits\n* Maintain a digital sleep diary and complete daily and weekly self-report ecological momentary assessments (EMAs)\n* Use a wearable device which will be used to collect and monitor physiological data",[334,335],"Major Depressive Disorder(MDD)","Insomnia Comorbid to Psychiatric Disorder",[337,338,339,340,341,342,343,344,345,346,347],"Lemborexant","Residual Insomnia","Major depressive disorder (MDD)","Ecological momentary assessments (EMA)","Wearable devices","Remote measurement-based care","Randomized controlled trial","Digital health monitoring","Feasibility trial","Pilot study","Placebo-controlled","2026-05-05",{"date":350,"type":45},"2026-05-08",{"date":352,"type":45},"2024-09-25",{"date":354,"type":22},"2028-04",{"name":51,"class":52},{"id":357,"slug":4,"hasResults":12,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":23,"phases":359,"briefSummary":67,"conditions":360,"keywords":361,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":366,"leadSponsor":368,"locationsCount":53},"100578338",{"count":63,"type":22},[65,66],[69,70,71,72],[60,74,75],"2026-04-29",{"date":364,"type":45},"2026-05-01",{"date":79,"type":45},{"date":367,"type":22},"2027-07-30",{"name":51,"class":52},{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":18,"minAge":377,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":23,"phases":379,"briefSummary":380,"conditions":381,"keywords":383,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":393,"locationsCount":53},"100554146","swift-canada-study-of-whole-blood-in-frontline-trauma-100554146","NCT06495294","SWiFT Canada (Study of Whole Blood in Frontline Trauma)","SWiFT Canada (Study of Whole Blood in Frontline Trauma): A Pilot Randomized Controlled Trial Assessing Prehospital Whole Blood Versus Component Therapy in Traumatic Hemorrhage","SWiFTCanada","Inclusion Criteria:\n\n* Patient who has suffered a traumatic injury\n* Attended by a participating Ornge AAS clinical team\n* Requires prehospital blood transfusion to treat major traumatic hemorrhage\n\nExclusion Criteria:\n\n* Pediatric (age \\\u003C16 or transported to pediatric trauma centre \\[if age unknown\\])\n* No intravenous or intraosseous access (should be assessed prior to opening box)\n* Knowledge that patient will object to being given blood transfusion for any reasons\n* Blood already administered on-scene, prior to arrival of the participating Ornge AAS","16 Years",{"count":63,"type":22},[25],"Traumatic injuries affect people of all ages, races, and socioeconomic backgrounds. The Global Burden of Disease study showed that globally in 2019, there were more than 4.4 million deaths due to injury. Furthermore, unintentional injuries are the leading cause of death for people aged 5-29 years worldwide. Uncontrolled bleeding accounts for a significant proportion of these deaths, with approximately 20% occurring in the first 24 hours and 40% occurring within the first 30 days.\n\nBlood transfusion is a life-saving treatment in the management of bleeding patients until bleeding is controlled in hospital, typically delivered through different blood components (red blood cells, plasma and platelets). These components are derived from a whole blood donation and are stored in separate bags (units). There are challenges in carrying separate blood products, such as additional weight in kit bags, and transfusing multiple blood products at the scene can delay transport to hospital.\n\nIn Ontario, Ornge Air Ambulance carries red blood cells and plasma to transfuse prehospital. However, a prehospital transfusion strategy has not been established and practice varies across the Canadian setting, and more broadly across the world.\n\nThis trial aims to investigate if carrying and transfusing two units of whole blood instead of four units (two red blood cells and two plasma) is feasible and leads to better outcomes for patients.",[382],"Trauma",[384,385,386,387],"prehospital","major hemorrhage","transfusion","emergency medicine",{"date":389,"type":45},"2026-05-06",{"date":391,"type":45},"2024-12-16",{"date":173,"type":22},{"name":51,"class":52},{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":18,"minAge":122,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":23,"phases":404,"briefSummary":405,"conditions":406,"keywords":408,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":410,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":53},"100368394","diffir---geriatric-distal-femur-fixation-versus-replacement-100368394","NCT04076735","DIFFIR - Geriatric Distal Femur Fixation Versus Replacement","DIFFIR: Geriatric Distal Femur Fixation Versus Replacement - A Randomized Controlled Trial of Acute Open Reduction Internal Fixation (ORIF) Versus Distal Femoral Replacement (DFR)","DIFFIR","Inclusion Criteria:\n\n* Male and female patients\n* 65 years and older\n* Isolated fracture of the distal femur (Classification 33)\n* Fracture is amendable to both treatments\n* Fracture is acute (within 2 weeks from time of injury)\n* Patient was ambulatory (with or without walking aids) prior to the injury\n* Independent or moderately frail with score of 3 to 6 on the Clinical Frailty Scale\n* Patient is able to read and understand English, French, or Spanish\n* Patient or substitute decision maker is able to provide written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Active or previous infection around the fracture (soft tissue or bone)\n* Open fracture\n* Bilateral femur fractures\n* Major vascular injuries requiring intervention, compartment syndrome and major neurologic injuries\n* Pathological fracture excluding osteoporosis\n* Previous surgical fixation or total knee replacement of the distal femur or proximal tibia\n* Previous surgical fixation or hemi\u002Ftotal replacement of the hip\n* Current or previous extensor mechanism (patellar tendon, quadriceps tendon, or patella fracture) disruption or repair\n* Polytrauma (Injury Severity Score \\> 15) or any associated major injuries of the lower extremities\n* Previous medical diagnosis of dementia\n* Medical or surgical contra-indication to surgery",{"count":403,"type":22},140,[25],"The current standard of care for most intra-articular distal femur fractures (above the knee joint) in geriatric patients is a surgical fixation using plates and screws to hold the fracture pieces in the correct position, until the fracture as healed.\n\nHowever, surgical fixation of these complex fractures in geriatric patients, is associated with significant complications, such as non-union (when the broken bone does not heal properly), infection and the need for revision surgery. Additionally, surgical fixation requires prolonged immobilization of of the affected limb (typically around 6-12 weeks post-operatively), which can lead to disability and other complications. Geriatric patients, especially those frail and with cognition impairment, are unable to adhere to the immobilization restrictions, which leads to an increased risk of fixation failure (broken bone does not heal).\n\nAnother treatment option for those patients is an acute distal femoral replacement (artificial knee), where damaged parts of the knee joint are replaced with artificial prosthesis. This procedure allows patients to walk immediately after the surgery and faster return to previous level of function, therefore avoiding the complications for immobilization.\n\nThere is a lack of guideline and evidence to suggest which surgical technique is best to provide superior function outcomes, lower complications and reduced costs. The proposed study seeks to answer this question by performing a large clinical trial comparing knee replacement versus surgical fixation in geriatric patients with distal femur fracture.",[407],"Distal Femur Fracture",[409],"Distal Femur Fracture; Geriatric fracture",{"date":389,"type":45},{"date":412,"type":45},"2021-10-01",{"date":414,"type":22},"2028-12-31",{"name":51,"class":52},{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":422,"eligibilityCriteria":423,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":424,"targetDuration":4,"studyType":251,"phases":4,"briefSummary":426,"conditions":427,"keywords":430,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":440,"locationsCount":53},"100604828","effects-of-abclo-fascial-approximation-device-in-patients-with-open-abdomen-on-respiratory-mechanics-100604828","NCT07154589","Effects of AbClo Fascial Approximation Device in Patients With Open Abdomen on Respiratory Mechanics","Effects of AbClo Fascial Approximation Device in Patients With Open Abdomen on Respiratory Mechanics (AbClo-Resp)","AbClo-Resp","Inclusion Criteria:\n\n* Adult patients aged 18 years or older\n* Patients admitted to an ICU\n* Patients with postoperative abdominal surgery with open abdomen\n* Patients treated with AbClo device\n* Patients intubated and mechanically ventilated\n* Patients treated with intravenous sedation with a sedation-agitation scale score of 1-3\n\nExclusion Criteria:\n\n* Transient criteria: Patients with severe hemodynamic instability, defined systolic blood pressure less than 75 mmHg or mean arterial pressure less than 60 mmHg despite vasopressor use\n* Transient criteria: Patients with severe bleeding diathesis, defined as the latest platelet count less than 20 · 109\u002FL, or the latest INR higher than 2.0\n* Patients with concurrent injuries to upper gastrointestinal tract that would preclude esophageal balloon insertion\n* Patients with bronchopleural fistula\n* Patients with measured and uncontrolled increased intracranial pressure",{"count":425,"type":22},18,"Patients who underwent an abdominal surgery and had the abdomen remain open are called to have an \"open abdomen\". To limit the risk of further widening of their wounds, surgeons can use AbClo, which is a non-invasive abdominal binding device, to keep the abdominal wall together (i.e., approximate the fascia). However, as the device also compresses on the abdomen and adjacent lungs, this study aims:\n\n* To assess whether the abdominal binding device causes changes in the pressure compressing the lungs, the lung volume, and the function of the lungs.\n* To assess whether adjusting the breathing machine can mitigate such negative changes.\n\nParticipants will already be on the abdominal binding device when joining the study. Measurements on various aspects of the lung function (including its physical properties and capability to oxygenate the blood) will be done before and after adjustment of the abdominal binding device to the pressure (measured in the device itself) recommended by the manufacturer, as well as after the surgery to close the abdomen.",[428,429],"Open Abdomen","Mechanical Ventilation",[431,432,433],"open abdomen","mechanical ventilation","transpulmonary pressure","2026-04-16",{"date":436,"type":45},"2026-04-22",{"date":438,"type":45},"2025-06-10",{"date":136,"type":22},{"name":51,"class":52},{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":445,"acronym":446,"eligibilityCriteria":447,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":448,"targetDuration":4,"studyType":23,"phases":450,"briefSummary":451,"conditions":452,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":462},"100497406","type-1-diabetes-virtual-self-management-education-and-support-100497406","NCT05756829","Type 1 Diabetes Virtual Self-management Education and Support","T1ME","Inclusion Criteria:\n\n1. Outpatients ≥18 years of age\n2. Physician diagnosis of type 1 diabetes\n3. Currently on an insulin pump or using multiple daily insulin injections.\n4. HbA1c ≥ 7.5% on most recent laboratory report or estimated from CGM\u002FFGM\\* report, within the last 4 months\n\n   \\*14 day look back window, with a wear rate of 70%, based on Estimated A1c or Glucose management Indicator (GMI)\n5. Has access to a mobile device or computer\u002Ftablet with a video camera\n6. Seen for at least one visit in the previous 6 months by participating certified diabetes educator at the selected diabetes clinic OR If a transitioning patient: Currently enrolled in a diabetes program below AND had at least one visit or touch-point prior in the previous 6 months by participating certified diabetes educator at on of our participating diabetes clinics\n7. OHIP coverage\n8. Currently using an active email address or be willing to obtain an email address\n9. Has consistent and reliable access to internet\n10. Willing and able to comply with scheduled in-person and virtual visits for 6 month intervention period\n\nExclusion Criteria:\n\n1. Diagnosed with non-Type 1 diabetes\n2. Unable to use a computer\u002Ftablet or mobile phone\n3. Pregnant\n4. On dialysis\n5. Unable to fluently speak or read English (self-reported)",{"count":449,"type":22},580,[25],"OVERVIEW: People living with type 1 diabetes (T1D) are expected to fit self-management and regular clinical consultations into busy lives. T1D self-management programs that offer frequent contact with care teams are most effective in helping patients achieve optimal glycemic control. However, this is difficult to deliver in the context of current T1D care which involves time-consuming in-person visits during working hours. The proposed study will test a virtual health care intervention to deliver \"high frequency, low touch\" care aimed at improving metabolic control, while reducing the burden on individuals and their healthcare teams.\n\nSTUDY DESIGN: A pragmatic multicenter, open-label, randomized trial to evaluate the short-term effectiveness of a multifaceted virtual health care intervention in improving glycemic control in individuals with T1D. Planned recruitment is 580 participants from 10 specialized T1D centres in Ontario.\n\nINTERVENTION: Our intervention will include 1) frequent, brief virtual visits between patients with T1D and certified diabetes educators (conducted in real time using a secure telemedicine video interface accessible from any PC, tablet or smart phone) combined with automatic appointment reminders, and 2) a centralized web-based platform to provide educational classes, tools, and resources for diabetes self-management. Virtual visits will be an adjunct to routine in-clinic visits for blood pressure monitoring, foot checks, and surveillance for other complications of diabetes. This approach aims to enable patients to receive more education and support than is feasible in traditional health care models, and in a way that is more seamless (i.e. results in fewer disruptions to their daily life) and tailored to their individual needs based on their stage in life.",[453],"type1diabetes","2026-04-15",{"date":456,"type":45},"2026-04-21",{"date":458,"type":45},"2023-05-10",{"date":460,"type":22},"2027-03-31",{"name":51,"class":52},9,{"id":464,"slug":465,"hasResults":12,"nctId":466,"briefTitle":467,"officialTitle":467,"acronym":4,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":23,"phases":471,"briefSummary":472,"conditions":473,"keywords":478,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":487,"completionDateStruct":488,"leadSponsor":490,"locationsCount":4},"100631955","phase-4-innovative-sternal-closure-techniques-evaluating-stratafix-and-dermabond-for-reduced-complications-in-cabg-patients-100631955","NCT07507409","Innovative Sternal Closure Techniques: Evaluating STRATAFIX™ and DERMABOND™ for Reduced Complications in CABG Patients","Inclusion Criteria:\n\n\\- Patients aged 18 years and older undergoing CABG surgery.\n\nExclusion Criteria:\n\n* Patients who refuse to participate in the trial.\n* Patients who do not read or speak English.\n* Patient with allergy to surgical adhesives or sutures",{"count":470,"type":22},401,[93],"The goal of this clinical trial is to learn if a new method of closing the breastbone after heart bypass surgery can improve healing and reduce complications in adults undergoing coronary artery bypass graft (CABG) surgery.\n\nThe main questions it aims to answer are:\n\nDoes this new closure method reduce infections and wound reopening? Does it improve healing, recovery, and overall patient outcomes?\n\nResearchers will compare patients who receive the new closure method to past patients who received the standard method to see if outcomes are better.\n\nParticipants will:\n\nReceive the new closure method during their surgery (as part of standard care) Be followed during their normal recovery up to their 6-week follow-up visit Complete a short quality-of-life questionnaire (about 10 minutes) Have their recovery assessed, including healing, complications, and hospital use\n\nResearchers will also look at quality of life, heart complications, hospital readmissions, antibiotic use, scar appearance, and overall costs to understand the full impact of the new method.",[474,475,476,477],"Cardiovascular Disease","Surgical Site Infection","Superficial Sternal Wound Infection","Mediastinitis",[479,480,481,482,483],"STRATAFIX","DERMABOND","Sternal Closure","Suture","CABG","2026-04-07",{"date":486,"type":45},"2026-04-13",{"date":364,"type":22},{"date":489,"type":22},"2028-05-01",{"name":51,"class":52},{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":498,"minAge":19,"maxAge":499,"enrollmentInfo":500,"targetDuration":4,"studyType":23,"phases":502,"briefSummary":503,"conditions":504,"keywords":507,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":4},"100631477","virtual-mindfulness-and-endometriosis-100631477","NCT07501182","Virtual Mindfulness and Endometriosis","Virtual Mindfulness-Based Therapy for the Management of Endometriosis Chronic Pelvic Pain: A Randomized Control Trial","Inclusion Criteria:\n\n1\\. Be between the ages of 18 and 50; 2. Have been symptomatic for six months or greater; 3. Clinical or surgical diagnosis of endometriosis (must have at least one of the following): i) Documented Clinical Diagnosis of endometriosis based on symptoms ii) Previous endometriosis surgery confirmed by histopathology iii) Imaging suggestive of endometriosis (ultrasound or MRI) iv) Receiving standard medical treatment for endometriosis including combined oral contraceptives, progestin, GnRH agonists, GnRH antagonist.\n\nExclusion Criteria:\n\n1. Diagnosis of other chronic pain condition, other than endometriosis;\n2. Recent surgical cases (\\\u003C 6 months)\n3. Vulvar pain diagnosis including vulvodynia, vaginismus\n4. Changes to current medical treatment or surgical intervention for endometriosis during the workshop period (10 weeks)\n5. Inability to complete the survey package\n6. Currently practicing mindfulness meditation.\n7. Have used the MyEndo phone application previously\n8. No internet access\n9. Non-English speaking.\n10. Unable to consent.","FEMALE","50 Years",{"count":501,"type":22},124,[25],"Endometriosis is a common gynecologic disease affecting 5-10% of women during their reproductive years.1 Symptoms are variable but can include debilitating pelvic pain, pain with intercourse, menstrual cycles, bowel movements and urination. This can interfere with patients' ability to work, attend school or have intimate relationships leading to serious effects on quality of life and mental health.2-5 Current management of endometriosis is predominantly medical and surgical. Unfortunately, these medications can come with potent side effects that may be intolerable to some patients. They can also be prohibitively expensive for patients without prescription coverage. Mindfulness is a psychological approach to bring the mind to the present moment and to enhance self-awareness. It includes the use of emotional regulation, reduced reactivity, and enhanced response flexibility.6 Mindfulness-based psychological treatments have shown to improve both pain and quality of life in patients with chronic pelvic pain.7-9 Despite the evidence for mindfulness-based therapy there is still limited use of this in the treatment of pelvic pain. The reasons for this are multifactorial and include financial and accessibility barriers. Virtual platforms can help bridge these inequities and support marginalized patient populations in getting access to treatments for endometriosis pain. Virtual mindfulness resources have been shown to improve health and decrease stress, anxiety, and depression.10,11 There is minimal evidence about online mindfulness platforms for chronic pain and none relating to endometriosis. There is great potential to use this medium to overcome many barriers to access, but more research is needed on its effectiveness in treating endometriosis pain. The primary objective of this research study is to determine if virtual mindfulness-based therapy improves quality of life in patients with endometriosis following completion of the ten-week virtual mindfulness-based workshop.",[505,506],"Endometriosis","Chronic Pain",[505,506,508],"Virtual Mindfulness","2026-03-24",{"date":511,"type":45},"2026-03-30",{"date":513,"type":22},"2026-03",{"date":515,"type":22},"2027-12",{"name":51,"class":52},{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":181,"sex":18,"minAge":524,"maxAge":525,"enrollmentInfo":526,"targetDuration":4,"studyType":251,"phases":4,"briefSummary":528,"conditions":529,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":53},"100327032","characterizing-dopamine-receptor-binding-in-treatment-resistant-depression-100327032","NCT03537794","Characterizing Dopamine Receptor Binding in Treatment Resistant Depression","Characterizing Dopamine D2 and D3 Receptor Binding in Treatment Resistant Depression","Inclusion Criteria:\n\n* Key inclusion criteria for the MDD patients:\n\n  * DSM-5 criteria for a Major Depressive Episode (MDE) within a MDD, confirmed through MINI diagnosis (Sheehan et al, 2015)\n  * Age between 25 and 55 years\n  * Hamilton Depression Rating Scale - 17 item (HRSD-17; Hamilton, 1960) \\> 14 (moderate to severe symptoms)\n  * Free of psychotropic medications for at least 5 half-lives before PET scanning\n  * Ability to undergo MRI scanning (absence of metal, pacemakers, etc.)\n  * For non-resistant patients: Previous history of response to an antidepressant, in order to increase signal to noise between resistant and non-resistant patients\n\nKey inclusion criteria for the Healthy Controls:\n\n* Ages between 25 and 55 years\n* Ability to undergo MRI scanning (absence of metal, pacemakers, etc.)\n\nExclusion Criteria:\n\nKey exclusion criteria for the MDD patients:\n\n* Pregnancy\u002Flactation\n* Medical condition requiring immediate investigation or treatment\n* Recent (\\\u003C 6 months)\u002Fcurrent history of drug abuse\u002Fdependence\n* Lifetime history of psychosis, other Axis I comorbidities are allowable\n* Use of any psychotropic use within 5 half-lives before the PET scanning\n* For non-resistant patients: Failure of \\> 2 antidepressant treatments of adequate dose and duration for current MDE.\n\nKey exclusion criteria for the Healthy Controls:\n\n* Pregnancy\u002Flactation\n* Medical condition requiring immediate investigation or treatment\n* Lifetime history of any psychiatric disorder\n* Lifetime history of receiving an antidepressant","25 Years","55 Years",{"count":527,"type":22},45,"It is estimated that 30% of individuals with Major Depressive Disorder (MDD) fail to respond to conventional antidepressant medication which accounts for over 1 million Canadians in their lifetime. Treatment resistant depression (TRD) patients also have greater psychiatric and medical comorbidity, poorer quality of life and increased suicidal ideation. Yet, there are few treatment strategies available to target TRD and there is a significant lack of evidence about how TRD differs from treatment-responsive depression. This proposal represents the first study to elucidate the neurobiology of TRD with a focus on dopamine receptor function throughout the brain, in order to inform treatment development and clinical characterization of TRD.The ultimate goal of this unique study is to characterize striatal and extrastriatal dopamine D2 and D3 receptor binding potential in patients with TRD, non-resistant MDD and healthy controls. The primary hypothesis is that TRD patients will exhibit greater D2\u002FD3 receptor binding potential compared to non-TRD patients in the following regions of interest: dorsolateral prefrontal cortex, orbitofrontal cortex, and ventral striatum. Secondarily, non-TRD patients will also demonstrate increased binding potential compared to healthy controls in the same brain regions. Whole brain analyses will allow us to take an exploratory approach to other brain regions that may differentiate TRD from non-TRD patients. Participants will be assessed at St. Michael's Hospital (SMH) and the Centre for Addiction and Mental Health (CAMH), which are within a 10 minute driving distance of each other. There will be 3 study visits following written informed consent. Eligibility will be confirmed at a screening visit at SMH where demographic information, including age, sex, education, and medication history will be obtained, as well as the administration of a structured Mini-International Neuropsychiatric Interview (MINI) for Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Axis I diagnoses (Sheehan et al, 2015), and an HRSD-17. Within two weeks of the screening visit, participants will undergo a structural magnetic resonance imaging (MRI) scan at SMH prior to the positron-emission tomography (PET) scan at CAMH. The order of the PHNO scans will be counterbalanced.",[530],"Treatment Resistant Depression","2026-03-12",{"date":533,"type":45},"2026-03-16",{"date":535,"type":45},"2025-08-22",{"date":537,"type":22},"2028-12",{"name":51,"class":52},{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":543,"acronym":4,"eligibilityCriteria":544,"healthyVolunteers":12,"sex":18,"minAge":545,"maxAge":546,"enrollmentInfo":547,"targetDuration":4,"studyType":23,"phases":548,"briefSummary":549,"conditions":550,"keywords":552,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":4},"100627965","first-appendectomy-using-revolve-surgical-robotic-arm-100627965","NCT07455487","First Appendectomy Using Revolve Surgical Robotic Arm","Inclusion Criteria:\n\n* Inpatients at Unity Health Toronto - St. Michael's Hospital scheduled for an elective appendectomy\n* Ages of 21-40 years old\n* Male and non-pregnant female patients (pregnancy test required)\n* No co-morbidities\n* Body Mass Index (BMI) between 18.5 and 25kg\u002Fm2\n* On no medications\n* Not taking any recreational drugs\n* Uncomplicated acute appendicitis (confirmed through abdominal ultrasound or abdominal computed tomography (CT) scan)\n* The pre-operative white blood cell count (WBC) must be between 4,500 - 15,000 cells per microliter.\n\nExclusion Criteria:\n\n* Any patient who does not have all the inclusion criteria described above.\n* Imaging of perforated appendix, free air, phlegmon, abscess, fluid collection, other any abdominal disease.\n* Any other abnormal laboratory test performed pre-operatively will cause the exclusion of the patient from the study.","21 Years","40 Years",{"count":205,"type":22},[25],"This study is testing a new surgical device called the Revolve Surgical System (RSS) during appendix removal surgery. The RSS is designed to help surgeons perform minimally invasive surgery with improved precision and stability while working at the patient's bedside, similar to standard laparoscopic surgery but with robotic assistance.\n\nThis will be the first time the device is used in patients. It will be evaluated in three adults with uncomplicated appendicitis who are already scheduled to have an appendectomy. The purpose of the study is to assess whether the device can be used safely and effectively and to better understand how it performs during surgery.",[551],"Appendicitis Acute",[553,554,555],"Robotics","Appendicitis","Laparoscopy","2026-03-02",{"date":558,"type":45},"2026-03-06",{"date":560,"type":22},"2026-04-01",{"date":562,"type":22},"2027-01-01",{"name":51,"class":52},{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":570,"eligibilityCriteria":571,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":572,"targetDuration":4,"studyType":23,"phases":574,"briefSummary":575,"conditions":576,"keywords":578,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":590,"leadSponsor":592,"locationsCount":53},"100626745","evaluating-novel-approaches-that-engage-and-support-vulnerable-patient-groups-to-equitably-access-primary-care-100626745","NCT07439627","Evaluating Novel Approaches That Engage and Support Vulnerable Patient Groups to Equitably Access Primary Care","Evaluating Novel Approaches That enGage And Support Vulnerable Patient Groups to Equitably Access Primary Care (ENGAGE): A Pilot Cluster Randomized Control Trial","ENGAGE","Inclusion Criteria:\n\n* Unattached adults (18+) made vulnerable who are seeking a primary care provider within the boundaries created by the Toronto Region Primary Care Workforce Planning Toolkit.\n\nExclusion Criteria:\n\n* Patients under 18 years old.\n* Patients above 18 years who have not been made vulnerable and are already registered and\u002For attached to a primary care organization within the boundaries created by the Toronto Region Primary Care Workforce Planning Toolkit.",{"count":573,"type":22},200,[25],"The goal of this initial clinical trial is to gather information for building a future national trial in Canada that can continuously look at different ways of helping people made vulnerable get a primary care provider. The trial will take place in the Toronto region and will help researchers decide how to plan the future trial.\n\nThe main question that this trial is aiming to answer is:\n\n• For those made vulnerable who do not currently have a primary care provider, will assistance from a Primary Care Connector trained specifically with knowledge of the local health system, help to better connect those people to primary care providers compared to written information alone?\n\nResearchers will compare giving participants the name of a provider that is accepting new patients in their area, to only giving participants existing information on how to find a provider, to see if giving the name of a provider accepting new patients works better to help people get connected to a provider.\n\nParticipants will:\n\n* Get the name of a primary care provider in their area who is accepting new patients or get existing information on how to find a primary care provider.\n* Call the provider to try and get an appointment or use the information given to find a provider.\n* Tell the study team if they have found a provider.",[577],"Access to Primary Care",[579,580,581,582,583,584,585],"Primary care access","Adaptive platform trials","People made vulnerable","Primary care connector","Primary care attachment","Primary care engagement","Cluster randomized control trial","2026-02-27",{"date":588,"type":45},"2026-03-03",{"date":513,"type":22},{"date":591,"type":22},"2026-07",{"name":51,"class":52},{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":599,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":601,"targetDuration":4,"studyType":23,"phases":603,"briefSummary":604,"conditions":605,"keywords":607,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":53},"100616132","phase-2-ecstasy-to-alleviate-severe-chronic-neuropathic-pain-trial-100616132","NCT07301632","Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial","Ecstasy to Alleviate SEvere Chronic Neuropathic Pain (EASE Pain) Trial: A Randomized Controlled Pilot Trial","EASEPain","Inclusion Criteria:\n\n* Consenting adults 18 years and older.\n* Diagnosis of chronic neuropathic pain (greater than 3 months in duration) by a clinician with specialized training in chronic pain, confirmed with the standardized Leeds Assessment of Neuropathic Symptoms and Signs questionnaire.\n* Suffering from moderate-to-severe pain as defined by\n* Baseline Patient Reported Outcomes Measurement System - Pain Interference (PROMIS-PI) score of greater than or equal to 60\n* An average pain intensity of greater than or equal to 5 on a 0-10 numeric rating scale,43\n* Treatment-refractory pain as defined by a failure of ≥2 medications recommended in the Canadian consensus guidelines on the management of CNP to generate self-reported meaningful improvement in symptoms.\n* For participants of childbearing potential, use of a highly effective or double-barrier methods of contraception. Abstinence is acceptable if it is the preferred and usual lifestyle of the participant.\n* Sufficient English skills to participate in psychotherapy.\n\nExclusion Criteria:\n\n* Past or current history of a psychotic disorder, mania, hypomania, bipolarity, current suicidal ideation, stimulant use disorder (i.e., cocaine, amphetamine, methamphetamine, MDMA, methylphenidate (Ritalin), etc , and any other substance use disorder within the past 12 months assessed by history and confirmed the Mini-International Neuropsychiatric Interview \\[MINI\\]. Other secondary psychiatric comorbidities (e.g., anxiety disorders, trauma related disorders, other personality disorders. etc.) will not be excluded\n* Participants with a history of suicide attempts are not excluded unless a significant risk of suicidal behavior is present at the time of screening as determined by the CRSS (Columbia suicide rating scale)\n* History of prior MDMA use (excluded to maintain blinding integrity)\n* Long QT syndrome, measured by an ECG with a QTc more than 450 ms for males, and 470 ms for females.\n* Presence of a relative or absolute contraindication to MDMA or Methylphenidate:\n* Pre-existing cardiovascular disorders evidenced in clinical records or disclosed on patient self-report, such as: uncontrolled hypertension (sustained blood pressure ≥160\u002F100 mmHg), angina (ongoing angina at rest, recent hospitalization for acute coronary syndrome within the past 3 months, or a history of revascularization (e.g., stenting or bypass surgery) within the past 6 months), arterial occlusive disease; heart failure, hemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction (within the past 6 months), potentially life-threatening arrhythmias (new-onset within the last 3 months), arrhythmias causing hemodynamic instability (SBP \\\u003C 90 mm Hg), or requiring urgent intervention (e.g., atrial fibrillation with rapid ventricular response or ventricular tachycardia), channelopathies, aneurysmal vascular disease (e.g., thoracic and\u002For abdominal aorta, intracranial, and peripheral arterial vessels), advanced arteriosclerosis\n* Cerebrovascular conditions: acute stroke or recent history of intracerebral hemorrhage (ischemic or hemorrhagic stroke occurring within the past 6 months)\n* Conditions at risk of elevation of blood pressure and increase heart rate, such as glaucoma, tension, agitation, thyrotoxicosis, pheochromocytoma\n* Motor tics and\u002For family history or diagnosis of Tourette's syndrome\n* Moderate to severe chronic kidney disease or kidney failure, such as requiring dialysis, significant treatment adjustments for kidney function, or regular nephrologist follow-up)\n* Moderate to severe liver disease, such as cirrhosis, a history of significant jaundice unrelated to temporary illness, or any liver condition requiring regular monitoring by a specialist).\n* Current treatment with selective serotonin reuptake inhibitors (SSRI's) and serotonin-norepinephrine reuptake inhibitors (SNRI's), tricyclic antidepressants, serotonin 5-HT1 receptor agonists (triptans) and 5-HT3 receptor antagonist antiemetics (risk of Serotonin Syndrome)\n* Hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption (methylphenidate contains lactose)\n* Seizure disorders\n* Pregnancy, or breastfeeding\n* Known hypersensitivity to study drugs or any study drug excipients\n* Medications that interact with study drugs including:\n* Any lifetime history use of any stimulant medication (e.g., Adderall, Vyvanse, Ritalin)\n* Caffeine intake within 24 hours\n* Monoamine oxidase inhibitors (MAOI) within 14 days (e.g. phenelzine, moclobemide, isoniazid, linezolid, phenelzine, harmine) due to risk of hypertensive crisis\n* CYP2D6 substrates and modifiers (such as: buproprion, fluoxetine, paroxetine, duloxetine, mirabegron).\n* Adrenergic agents (e.g. clonidine) risk of sudden death\n* Vasopressor agents (ephedrine pseudoephedrine)\n* Coumarin anticoagulants (e.g., warfarin),\n* Anticonvulsants (e.g., phenobarbital, diphenylhydantoin, primidone)\n* Anti-psychotics and inhibitors of dopamine uptake (e.g. haloperidol, DOPA, tricyclic antidepressants)\n* Concomitant medication that could prolong ECG QT interval (e.g. ondansetron, risperidone, methadone)\n* Selective Serotonin Reuptake Inhibitors (citalopram, sertraline, fluvoxamine, escitalopram)\n* Selective Norepinephrine Uptake Inhibitors (e.g. venlafaxine, duloxetine); Serotonergic Drugs (e.g. dextromethorphan, fentanyl, St. John's Wort, tramadol, 5-hydroxytryptophan); serotonin 5-HT1 receptor agonists (triptans) and 5-HT3 receptor antagonist antiemetics due risk of Serotonin Syndrome which is a potentially life- threatening condition\n* Currently engaged in psychotherapy for CNP (other psychotherapy for non-CNP is allowed).\n* Any other clinically significant medical illness that, in the opinion of the investigator, may interfere with the interpretation of the study results or constitute a health risk for the participant if they take part in the study.",{"count":602,"type":22},40,[66],"This is a Health Canada regulated internal pilot study designed to assess the feasibility, tolerability, and preliminary efficacy of 3, 4-methylenedioxymethamphetamine hydrochloride capsules-AT for chronic neuropathic pain to inform a larger, fully powered multi-center study. This is an interventional, randomized, 2-arm parallel, triple blinded study.\n\nThe total study duration is 2 years.\n\nParticipants will receive preparatory psychotherapy session during week 2 and week 4 followed by a combined single dosing session with psychotherapy during week 6. Integrative psychotherapy will follow at weeks 6, 8, 12, and 16.\n\nFollow up for primary clinical endpoint at week 16; final follow up for secondary clinical endpoint at 16-weeks.\n\nParticipants will be asked to complete adjunctive home psychotherapy in the form of online modules. Data collected will be entered in electronic case report form (REDCap Academic).",[606],"Chronic Neuropathic Pain",[608,606],"3, 4-methylenedioxymethamphetamine hydrochloride","2026-02-10",{"date":611,"type":45},"2026-02-13",{"date":613,"type":45},"2026-01-30",{"date":615,"type":22},"2028-12-01",{"name":51,"class":52},{"id":618,"slug":619,"hasResults":12,"nctId":620,"briefTitle":621,"officialTitle":622,"acronym":623,"eligibilityCriteria":624,"healthyVolunteers":12,"sex":18,"minAge":625,"maxAge":4,"enrollmentInfo":626,"targetDuration":4,"studyType":23,"phases":628,"briefSummary":629,"conditions":630,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":632,"lastUpdatePostDateStruct":633,"startDateStruct":634,"completionDateStruct":636,"leadSponsor":638,"locationsCount":53},"100498912","phase-3-effect-of-a-healthy-food-voucher-on-blood-glucose-control-in-people-with-type-2-diabetes-or-prediabetes-100498912","NCT05776420","Effect of a Healthy Food Voucher on Blood Glucose Control in People With Type 2 Diabetes or Prediabetes","Effect of a Healthy Food Voucher on Blood Glucose Control in People With Type 2 Diabetes or Prediabetes: a Randomized Controlled Trial","VOUCH4DIABETES","Inclusion Criteria:\n\n* hemoglobin A1c 6.0 to 11.0\n* report food insecurity or financial insecurity\n\nExclusion Criteria:\n\n* live with a current study participant\n* life expectancy \\\u003C 6 months\n* multiple life-threatening allergies to common foods\n* require total parenteral nutrion\n* blood dyscrasia that interferes with hemoglobin A1c interpretation\n* hemoglobin A1c \\>11","19 Years",{"count":627,"type":22},390,[304],"This randomized controlled trial (RCT) will determine if access to a voucher for healthy foods reduces blood sugar levels among people living on a low income who have type 2 diabetes or elevated blood sugar.",[631],"Diabete Type 2","2026-02-05",{"date":609,"type":45},{"date":635,"type":45},"2023-03-21",{"date":637,"type":22},"2027-04-01",{"name":51,"class":52},{"id":640,"slug":641,"hasResults":12,"nctId":642,"briefTitle":643,"officialTitle":644,"acronym":4,"eligibilityCriteria":645,"healthyVolunteers":181,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":646,"targetDuration":4,"studyType":23,"phases":648,"briefSummary":649,"conditions":650,"keywords":653,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":657,"lastUpdatePostDateStruct":658,"startDateStruct":660,"completionDateStruct":662,"leadSponsor":664,"locationsCount":205},"100571146","multiplo-tphiv-self-test-100571146","NCT06716450","Multiplo Tp\u002FHIV Self-Test","A Study to Evaluate the Accuracy, Usability and Readability of the Multiplo® TP\u002FHIV Antibody Self-Test Performed by Observed Intended Users in Canada and the Impact of Peer-led HIV and Syphilis Care Among People Experiencing Homelessness in Toronto","Inclusion Criteria:\n\n* Are ≥18 years of age.\n* Can speak\u002Fread\u002Fwrite English or French.\n* Have presented for voluntary testing for HIV and\u002For syphilis infection in the clinic or community-based setting.\n* Are willing to participate in the study site's standard of care HIV and syphilis counselling and testing program and receive the study site's standard of care test results.\n* Are willing to be a participant in the study.\n* Can provide informed consent i.e. understand and sign or instruct the Observer to sign the informed consent form.\n* Can complete the required testing on the allocated testing day.\n* Are willing to provide the necessary fingerstick and venipuncture blood for use in the study protocol testing methods.\n* Are of unknown HIV and syphilis status (last HIV and syphilis negative test must be a minimum of 3 months prior).\n\nExclusion Criteria:\n\n* Do not meet the inclusion criteria.\n* Are known HIV and\u002For syphilis positive.\n* Have ever tested positive for syphilis or HIV at any time.\n* Have any experience in conducting rapid point-of-care tests on patients for HIV, syphilis or any other infectious disease.\n* Are familiar with the Multiplo® TP\u002FHIV Self-Test.\n* Are investigator site employees or immediate family members of sponsor or investigator sites.\n* Have participated in any prior, or concurrent trial of HIV and syphilis self-tests.\n* Are a practicing medical healthcare professional (doctor, nurse or HIV counsellor that performs HIV testing with Rapid Tests).\n* Any condition which, in the opinion of the Observer, would make the participant unsuitable or unsafe for enrolment or could interfere with the completion of the assessment, consent form and questionnaire etc. or bias the outcome (e.g. being unable to see\u002Fread by forgetting to bring reading glasses, being intoxicated, acute sickness, visibly distressed).",{"count":647,"type":22},900,[25],"To help reach the undiagnosed living with HIV and\u002For syphilis in Canada, self-tests for HIV and Syphilis may have substantial utility for increased identification of infected individuals through their relative ease of use and portability, as well as their ability to deliver rapid, actionable results while the care provider still has access to the patient. MedMira Laboratories Inc. (Halifax, Nova Scotia, Canada) has developed a point-of-care (POC) test to detect HIV and Syphilis antibodies in fingerstick blood samples that is under final review by Health Canada for use by trained Healthcare professionals. A self-test version of this test, with simplified instructions for use has been developed for investigational studies. The goal of the following study sponsored by REACH Nexus is to provide evidence that untrained lay persons \u002F intended users can perform the Multiplo Tp\u002FHIV Self-Test without any increased risk of obtaining erroneous results.",[651,652],"HIV Infection","Syphilis Infection",[654,655,656],"self-test","device trial","screen test","2026-01-23",{"date":659,"type":45},"2026-01-27",{"date":661,"type":45},"2025-06-12",{"date":663,"type":22},"2026-12-10",{"name":51,"class":52},{"id":666,"slug":667,"hasResults":12,"nctId":668,"briefTitle":669,"officialTitle":670,"acronym":4,"eligibilityCriteria":671,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":672,"targetDuration":4,"studyType":23,"phases":674,"briefSummary":675,"conditions":676,"keywords":680,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":683,"lastUpdatePostDateStruct":684,"startDateStruct":686,"completionDateStruct":688,"leadSponsor":689,"locationsCount":53},"100560036","brief-skills-for-safer-living-brief-sfsl-100560036","NCT06571916","Brief Skills for Safer Living (Brief-SfSL)","Investigating the Efficacy of a Novel Therapy for Suicide Risk in Adults: A Randomized Controlled Trial of an Intensive Single Session of \"Brief Skills for Safer Living\"","Inclusion Criteria:\n\n* Suicidal ideation in the past week\n* Access to a computer or phone with a camera\n* Access to internet\n* Access to an emergency contact and hospital within commuting distance\n* Not receiving other psychotherapy\u002Fcounselling services concurrently\n* Willing to have the session recorded to determine therapy fidelity\n* Any psychiatric diagnosis is allowed\n* Follow-up visits with a psychiatrist and\u002For family doctor where a psychotherapeutic modality (e.g., Dialectical Behavioural Therapy, psychodynamic therapy, etc.) is not being used are allowable\n\nExclusion Criteria:\n\n* Inability to undergo psychotherapy in English\n* Presence of cognitive impairment that would limit consent and understanding of Brief Skills for Safer Living\n* Active psychosis\n* Unwilling or unable to provide informed consent\n* Previously enrolled in the Brief-SfSL pilot study\n* Unwilling or unable to communicate verbally",{"count":673,"type":22},150,[25],"The goal of this project is to assess the efficacy of Brief-Skills for Safer Living (Brief-SfSL) in a randomized control trial. The investigators will be testing 150 participants Canada-wide, half of which will be randomized to receive Brief-SfSL (B-TAU) and the other half will be randomized to receive Brief-SfSL after a 3 month waitlist (WL-TAU). The main questions this study seeks to answer are:\n\n* Is B-TAU more efficacious than WL-TAU for reducing suicidal thoughts at 3 months?\n* Is B-TAU more efficacious than WL-TAU at 3 months for reducing depression severity, anxiety, and anhedonia?\n* Is B-TAU more efficacious than WL-TAU at 3 months for improving social connectedness, emotional regulation, functioning (work, life, social), executive control and social problem-solving?\n* Are adverse events equivalent between B-TAU and WL-TAU at 3 months?",[677,678,679],"Suicide Prevention","Suicide","Suicide and Self-harm",[681,682],"suicide","psychotherapy","2026-01-20",{"date":685,"type":45},"2026-01-22",{"date":687,"type":45},"2025-11-17",{"date":414,"type":22},{"name":51,"class":52},""]